

US-China Relations and Geopolitical Uncertainty

BCG Perspectives









China is slowing but already a heavyweight (Trade, Tech, F500...)

Expanding influence & market presence, also creating frictions

EVs a flashpoint as China seeks to lead in higher-tech industries



"Trade war" persists Trump<->Biden, multiple trade barriers

US has substantially reduced trade with China since 2018, but level of China dependence, "reshoring" potential vary by sector



MNCs find China doing business tougher

Some still "all-in" on China supply chain, others "+1" or "Reshore"

MNCs building risk sensing muscle to make contingent moves






Economic giant | China > 20% share in many dimensions, rivaling US & EU



Copyright © 2024 by Boston Consulting Group. All rights reserved



Trade locus | Emerging & industrialized economies trade extensively with China




Note: Based on 2021 trade data, 2019 data was used for Libya, Ghana, Afghanistan, Mali Source: UN Comtrade; BCG analysis



China Inc | More Chinese companies in Fortune 500 now than US / Europe Big3


Number of companies in Fortune 500, by HQ country






Ex. EVs: China OEMs and China exports penetrating global EV market

China EV market penetration



China exports of passenger vehicles (\$B)



Note: Volvo & Polestar counted as Chinese OEMs


Source: IHS February 2024

Copyright © 2024 by Boston Consulting Group. All rights reserved.






GDP per capita trend and GDP by country





China-US frictions | Tough US policy toward China persists, multiple policies

US-China trade barriers have carried over from Trump to Biden



Tough China laws have broad support in US Congress

Exports of US technology (incl. tech offshore) to 100+ China entities restricted

UFLPA⁴ Embargos on imports with content originating in Xinjiang

To get EV subsidy, China ("foreign entity of concern") cannot be used to source components

Tougher "Buy American" provisions to qualify for US government procurement

Chips Act "Guard-rail" provisions restricting grant recipients from large investments in China

rse | Proposal to begin screening US outbound 7 " | investment on national security grounds

In law










Biden has built on Trump-era tariffs - different degrees of potential impact



copyright © 2024 by Boston Consulting Group. All rights reserved.



US has significantly reduced trade with China since start of "Trade War" (2018-)

Change (abs.) in US imports ¹ ('18-'23) US imports 2018 - 2023 (real 2010 \$B USD)		2018 imports	EU27	Mexico	China	Canada	ASEAN	Japan	India	Mercosur ³	RoW ⁴	Net change	2023 Imports
Total 2018 Imports		2,298	413	327	536	234	182	141	51	30	383		
Industrial Goods	Auto - Components	228	6.4	21.6	-10.9	2.7	6.9	-2.7	2.3	-0.1	5.6	31.9	260
	Auto - Vehicles	206	8.9	12.5	0.3	-3.9	0.1	-4.1	-1.1	0.1	11.5	24.4	230
	Metals	155	3.7	3.5	-7.1	11.4	1.5	-0.2	1.7	0.9	12.0	27.5	183
	Electrical machinery	147	7.3	10.6	-9.6	1.3	12.4	0.5	1.3	0.6	7.6	32.0	179
	Chemicals	154	4.3	3.7	-5.6	3.8	4.8	-0.4	1.7	-0.2	6.0	18.1	173
	Mechanical machinery	152	7.3	3.2	-16.8	2.4	5.1	1.0	1.2	0.5	4.9	8.8	161
	Agribusiness	89	1.8	5.9	-1.4	6.7	-1.3	0.2	-0.3	1.9	5.8	19.2	108
	Aerospace	63	-3.9	0.9	-0.6	3.3	-1.2	-3.1	0.3	-0.5	0.2	-4.7	59
	Non-metals	24	0.6	0.9	-3.3	0.1	1.1	-0.2	0.6	-0.1	1.0	0.7	25
	Mining	4	-0.1	0.0	0.0	0.2	-0.1	0.0	0.0	0.0	-0.1	0.1	4
Tech, Media & Telco	Consumer Electronics	194	1.5	1.1	-25.0	0.1	16.8	-1.1	4.6	0.2	7.8	5.9	199
	Data Center Eqpt.	84	0.7	-2.0	-22.1	0.3	16.6	0.7	1.0	0.0	14.6	9.8	94
	Semiconductors	43	1.4	-0.1	-2.3	-0.5	6.1	-0.5	1.6	0.0	6.9	12.7	56
Consumer Goods	Consumer Durables	84	1.6	4.3	-15.7	0.6	8.1	-0.2	0.3	0.1	1.7	0.8	85
	Fashion & Luxury	156	1.6	-0.2	-25.9	-0.4	3.5	-0.3	0.6	-0.1	2.5	-18.8	137
	Packaged Food	66	1.0	7.7	-1.5	5.8	1.2	0.1	0.4	0.7	2.8	18.2	84
Health Care	Bio-Pharma	137	40.6	0.1	3.0	0.4	4.1	3.1	3.7	0.3	-2.6	52.6	190
	MedTech	66	2.1	5.7	-0.9	0.2	1.8	-0.5	0.1	0.1	4.0	12.5	79
Other		246	8.9	2.3	-4.2	0.4	9.1	-0.7	0.5	-1.4	-1.1	13.8	260
Total/Change in trade value			95.8	81.6	-149.6	34.8	96.8	-8.2	20.5	2.9	90.9	265.6	
Total 2023 Imports			509	409	387	268	279	133	71	34	474		2,564

^{1.} Energy excluded, 2.Japan + Korea, 3. Argentina, Brazil, Paraguay, and Uruguay, 4. Rest of World; Source: S&P Global Trade Atlas, EIU; BCG analysis




MNC business sentiment in China unfavorable, geopolitics a key factor

US-China Business Council Member Survey, 2023


2023 Rank	2022 Rank	Change	Top challenges for US businesses
1	2		US-China relations: Geopolitics or domestic politics
2	6		Data, personal information, and cybersecurity rules
3	7		Export controls, sanctions, and investment screenings
4	12		Competition with Chinese companies (state owned or private)
5	13		Licenses and approvals
6	-		Uneven enforcement of laws and regulations
7	16		International travel
8	16		Transparency
9	10		Intellectual property protection
10	8		Industrial policy

Key facts on declining sentiment











10

MNCs weighing options to diversify beyond China -- no perfect solution

Degree of change

















All-in on China

Double-down on China as base for sourcing and manufacturing

- Maximize scale efficiencies, deep supplier networks
- High exposure to geopolitical and other China risks
- Rising labor costs

China +1

Moving some sourcing and production beyond China, with key inputs still China-origin

- Multi-sourcing, redundant capacity
- New platforms to export to core markets
- China sourcing risk persists
- Relocation challenges, greater cross-border complexity

Global supply chains

Expand sourcing options across a variety of locations

- Significantly less China risk
- Local-for-local solutions
- Partially higher costs
- Significant supply chain overhaul

Reshoring

Produce in or close to the core end-markets

- Minimize China risk
- Take advantage of onshoring incentives
- Much higher costs
- Significant supply chain overhaul with uncertain results, supply constraints

Companies are developing "risk sensing" to monitor carefully, act quickly


Example - US MedTech player

Specific signposts for client to track



Process to monitor and act on signposts

- Define "sensing" work owners and potential crossfunctional and/or regional teaming structures
- Define overall resource commitment, reporting cadence, degree of formalization
- Optimize data & tools, use of outside vendors
- Classify adverse events per impact on business and likelihood



Note: Approximate position, to be refined and recalibrated per monitoring

Actors

Government Market Internal

Red flag - Immediate need for action

Disclaimer

The services and materials provided by Boston Consulting Group (BCG) are subject to BCG's Standard Terms (a copy of which is available upon request) or such other agreement as may have been previously executed by BCG. BCG does not provide legal, accounting, or tax advice. The Client is responsible for obtaining independent advice concerning these matters. This advice may affect the guidance given by BCG. Further, BCG has made no undertaking to update these materials after the date hereof, notwithstanding that such information may become outdated or inaccurate.

The materials contained in this presentation are designed for the sole use by the board of directors or senior management of the Client and solely for the limited purposes described in the presentation. The materials shall not be copied or given to any person or entity other than the Client ("Third Party") without the prior written consent of BCG. These materials serve only as the focus for discussion; they are incomplete without the accompanying oral commentary and may not be relied on as a stand-alone document. Further, Third Parties may not, and it is unreasonable for any Third Party to, rely on these materials for any purpose whatsoever. To the fullest extent permitted by law (and except to the extent otherwise agreed in a signed writing by BCG), BCG shall have no liability whatsoever to any Third Party, and any Third Party hereby waives any rights and claims it may have at any time against BCG with regard to the services, this presentation, or other materials, including the accuracy or completeness thereof. Receipt and review of this document shall be deemed agreement with and consideration for the foregoing.

BCG does not provide fairness opinions or valuations of market transactions, and these materials should not be relied on or construed as such. Further, the financial evaluations, projected market and financial information, and conclusions contained in these materials are based upon standard valuation methodologies, are not definitive forecasts, and are not guaranteed by BCG. BCG has used public and/or confidential data and assumptions provided to BCG by the Client. BCG has not independently verified the data and assumptions used in these analyses. Changes in the underlying data or operating assumptions will clearly impact the analyses and conclusions.



bcg.com

